Timing Estrogen After MenoPaUSe

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2017-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the current study is to test whether the effect of estrogen on insulin metabolism depends on the timing of treatment relative to when a woman went through menopause. The investigators hypothesize that estrogen will improve insulin sensitivity in early postmenopausal women, but decrease insulin sensitivity in late postmenopausal women.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hormone Replacement Therapy and Insulin Action: A Double-Blind, Parallel, Placebo-Controlled Hormone Intervention Study in Postmenopausal Women

NCT00005769

Menopause

UNKNOWN PHASE2

The Effects of Estrogen Withdrawal on Mood Symptoms in Women

NCT00060736

Perimenopausal Depression Post Menopausal Healthy +1 more

COMPLETED

Postmenopausal Women Estrogen and Progesterone Infusion

NCT00455741

Postmenopause Aging

COMPLETED PHASE1/PHASE2

A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women

NCT00820664

Postmenopausal Symptoms

COMPLETED PHASE1

Bioidentical 'Natural' Hormone Evaluation in Early Menopause

NCT00302731

Menopause

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Large clinical trials have shown a reduced incidence of type 2 diabetes in postmenopausal women randomized to estrogen-based hormone therapy compared to placebo. Moreover, studies suggest development of diabetes is reduced in postmenopausal women who used hormone therapy for a part of the postmenopausal period compared to women who never used hormone therapy. Consistent with this, our preliminary data suggest that the timing of estrogen treatment relative to the menopause may be an important determinant of whether there are favorable effects on insulin action. Our observations suggest that estrogen improves insulin sensitivity in early postmenopausal women, but may decrease insulin sensitivity in those more than 10 years past menopause. More and more studies suggest estrogens have divergent effects on cardiovascular risk when initiated close to the onset of menopause rather than distant from the menopause; we hypothesize this is also true for diabetes risk. The goal of this study is to determine whether the effects of estrogen on insulin metabolism are different in women who are early postmenopausal compared to late postmenopausal. To meet our goal, we propose to measure insulin sensitivity in women who are within 6 years of the onset of menopause or more than 10 years beyond the menopause and who have not used hormone therapy previously. All women will be studied on two separate occasions, one day with and one day without short-term (1 week) treatment with transdermal estradiol. We expect that estradiol will increase insulin sensitivity in early postmenopausal women and decrease insulin sensitivity in late postmenopausal women. We also expect that estrogen receptors in fat and muscle may change with increasing time after menopause. Thus, we will collect fat and muscle biopsies to compare changes in estrogen receptors between early and late postmenopausal women and in response to 1 week of estradiol treatment. We believe these studies will provide evidence for a benefit of estradiol on insulin sensitivity when administered early, but not late, after menopause; likely contributing to delayed onset of type 2 diabetes in postmenopausal women.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insulin Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Early Postmenopausal

Postmenopausal women within 6 years of last menses who never used estrogen-based hormone therapy

Group Type ACTIVE_COMPARATOR

Estradiol

Intervention Type DRUG

1 week of transdermal estradiol (0.15mg)

1 week of transdermal placebo

Late Postmenopausal

Postmenopausal women more than 10 years since last menses who never used estrogen-based hormone therapy

Group Type ACTIVE_COMPARATOR

Estradiol

Intervention Type DRUG

1 week of transdermal estradiol (0.15mg)

1 week of transdermal placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Estradiol

1 week of transdermal estradiol (0.15mg)

1 week of transdermal placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Climara

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* aged 45-70 yr
* postmenopausal (no menses ≥12 mo or bilateral oophorectomy and FSH \>30 IU/L)
* ≤6yrs or ≥10yrs of menopause (last menses or oophorectomy)
* BMI \<30 kg/m2 and weight stable (±2kg in past 2mo)
* non-smokers
* sedentary to moderately active (\<3 days/wk of structured exercise)
* naïve to estrogen-based hormone therapies (previous use ≤6 months)
* CBC, CMP and TSH values within normal ranges specified by lab

Exclusion Criteria

* underwent a partial hysterectomy (i.e., one or both ovaries left intact)
* underwent menopause (natural, chemical, or surgical) prior to age 45yr
* are between \>6yr and \<10yr of menopause (last menses or oophorectomy)
* previously used (\>6 mo) or are currently using any formulation of estrogen-based HT (e.g., oral Premarin, transdermal 17beta-estradiol, selective estrogen receptor modulators)
* have T2DM or are being treated with glucose-lowering/ insulin sensitizing medications
* have uncontrolled hypertension (SBP\>140 and/or DBP\>90 mmHg)
* have hypertriglyceridemia (\>400 mg/dL)
* have contraindications to estrogen therapy (history of venous thromboembolism, heart disease, myocardial infarction, hormone sensitive cancer)
* have contraindications to biopsies (severe anemia, blood clotting disorders)

Minimum Eligible Age

45 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes